Human genetics seeks a way to improve human health on a global scale. Expectations are 51 running high for polygenic risk scores (PRSs) to be translated into clinical practice to predict 52 an inborn susceptibility to health risks. While risk stratification based on PRS is one way to 53 promote population health, a strategy to utilize genetics to prioritize modifiable risk factors 54 and biomarkers driving heath outcome is also warranted. To this end, here we utilized PRSs 55 to comprehensively investigate the association of the genetic susceptibility to complex traits 56 with human lifespan in collaboration with three worldwide biobanks (ntotal = 675,898). First, 57
Human disease risks can be explained by the combinations and interactions of inherited 76 genetic susceptibility, acquired environmental exposures, and lifestyle factors 1 . One of the 77 goals of medical research is to identify individuals at health risks both at the time of birth and 78 later in life, and to provide them medical attention when necessary. Polygenic risk scores 79 (PRSs) have successfully shown their predictive ability to idenitify those with a several-fold 80 higher inherited risk of a given disease or condition 2 . Both an increase in statistical power 81 and ethnic diversity in genetic studies-accelerated by nation-wide biobanks-have been 82 instrumental in accurately predicting disease onset by PRSs 3-6 . Stratification of health risks 83 based on PRSs would be one of the strategies to improve population health through targeted 84 prevention. Nevertheless, the genetic risk itself cannot be modified. For many complex 85 human traits, environmental exposure and lifestyle are also of great importance, such as 86 cigarette smoking 7 and dietary habits 8 . The accurate identification of risk factors that affect 87 not only disease onset but also long-term health outcomes would contribute to population 88 health, because these factors can be modified by medical intervention. 89
Observational studies have been attempting to identify monitorable risk factors and 90 biomarkers that are correlated with the health outcomes (e.g., high low-density lipoprotein 91
[LDL] cholesterol levels and the development of myocardial infarction). Nevertheless, the 92 observational studies are inevitably laden with the pervasive issue of difficulty in inferring the 93 cause-and-effect direction. A randomized controlled trial (RCT) is considered the gold 94 standard to derive the effect of the exposure on the outcome free from unknown confounders 9 . 95
In the above example, if a medical intervention to decrease the LDL cholesterol level leads 96 6 to the decreased incidence of myocardial infarction at the population level, we could estimate 97 that the high LDL cholesterol levels cause the development of myocardial infarction. The 98 limitations of RCTs are, however, that they require a considerable amount of human and 99 economic resources and are not always ethically feasible. 100
To address this, we here aimed to identify complex human traits affecting human lifespan, 101 a health outcome of extreme importance and interest, by utilizing PRSs. The association of 102 genetic susceptibility with lifespan would enable the prioritization of common risk factors and 103 biomarkers, which could drive mortality in the current generation, among a variety of 104 phenotypes that could be monitored in clinics. Furthermore, integration with deep-phenotype 105 records and follow-up data in biobanks would enable us to pinpoint specific comorbidities and 106 death causes that lead this association. Given the large genetic and environmental 107 8 human lifespan. We next performed replication studies of the association of the PRSs with 137 lifespan in UK Biobank and FinnGen. We finally meta-analyzed these associations across 138 the three cohorts. 139 140
Association study of clinical biomarkers with human lifespan 141
First, in order to identify candidate clinical biomarkers correlated with human lifespan, we 142 conducted an observational association study of these phenotypes with the lifespan on 143 BioBank Japan. After the Bonferroni correction for multiple testing, 38 out of 45 clinical 144 phenotypes showed a significant association with age at death (Figure 1a ; Summary results 145 are in Supplementary Table 2 ). The top traits associated with a shorter lifespan were low 146 albumin, high γ-glutamyl transpeptidase, and increased height. The effect of a one standard 147 deviation (SD) increase in each trait on mortality resulted in a hazard ratio (HR) of 0.80 [0.79-148 0.81], 1.16 [1.15-1.17], and 1.30 [1.27-1.32] (P = 3.3 × 10 −287 , 1.1 × 10 −224 , and 8.3 × 10 −186 ), 149 respectively. These results were consistent with the previous epidemiological studies in other 150 cohorts [13] [14] [15] [16] . 151
To investigate how the association of clinical biomarkers with human lifespan is shared 152 across different populations, we next performed the same observational study in UK Biobank 153 using the 20 clinical phenotypes that were recorded in both UK Biobank and in BioBank 154 Japan (Supplementary Figure 2) . We again observed significant associations of the 155 quantitative traits with lifespan in 17 out of 20 traits. Of note, 14 among the 15 traits with 156 significant association in BioBank Japan showed directionally concordant associations with 157 lifespan in UK Biobank. The only trait that showed directionally discordant association was 158 body mass index (BMI). While a lower BMI was significantly associated with a shorter lifespan 9 in Biobank Japan, a higher BMI showed significant association with a shorter lifespan in UK 160
Biobank. This discordant result could be attributed to differences in the participation criteria 161 (i.e. hospital-based recruitment in BioBank Japan and healthy volunteers in UK Biobank) and 162 differences in the health burden of obesity across populations, which warrants further 163 replication studies in different cohorts. 164
A weakness of the epidemiological associations was, however, that it was difficult to 165 conclude whether the variations in clinical measurements had caused the variations in 166 lifespan, or they were just correlations. For example, a decreased albumin level was 167 associated with a shorter lifespan, but this did not mean that low albumin caused high 168 mortality. Rather, the decline in general health and nutritional status, which led to high 169 mortality, might have resulted in low albumin levels. In BioBank Japan, we first randomly split the entire cohort into 10 sub-groups and performed 187 genome-wide association studies (GWASs) on 45 quantitative traits. We then performed a 188 10-fold leave-one-group-out (LOGO) meta-analysis, derived the PRSs in one remaining sub-189 group, and associated them with lifespan. We meta-analyzed the statistics of the lifespan 190 association obtained from the ten sub-groups. In UK Biobank, when individual-level 191 phenotype data is available, we adopted the LOGO approach. Otherwise, we derived the 192
PRSs from public large-scale GWAS statistics, and associated the PRSs with lifespan in the 193 cohort. As a secondary analysis, we also associated the PRS with parental lifespan in UK 194
13
Biobank. In FinnGen, we derived the PRSs from UK Biobank GWAS summary statistics or 195 public large-scale GWAS statistics, and associated the PRS with lifespan in the cohort. 196
Finally, we performed trans-ethnic meta-analysis. 197
Association study of PRSs of complex traits with human lifespan in BioBank Japan 198
Next, in order to prioritize the clinical traits affecting human lifespan, we utilized genetic 199 information. PRS is supposed to simulate the genetic predisposition towards the investigated 200 trait 1 . Thus, the association of the PRS of the investigated trait with lifespan can be 201 considered as less susceptible to the confounding factors such as a decline in general 202 health 17, 18 . PRSs should be constructed from the genetic studies of the same population 5,19 , 203
and BioBank Japan has been the largest study of East Asian populations to date. 204
Conventionally, when independent large-scale GWAS statistics with matched population and 205 a sufficient sample size are not available for constructing PRSs, a strategy to split the study 206 cohort into two groups (i.e., discovery group to conduct GWASs and a validation cohort to 207 derive the PRSs) has been used. This strategy compromises accurate estimates in GWAS 208 statistics using maximum samples or lowers the statistical power in PRS validations, 209 depending on how the cohort is split. To address this, we adopted a 10-fold leave-one-group-210 out (LOGO) meta-analysis approach in the derivation of PRSs in order to validate the PRSs 211 in participants independent from GWAS while retaining as much sample size and statistical 212 power as possible. Briefly, we first conducted GWASs on 45 clinical phenotypes by randomly 213 splitting the whole cohort into ten sub-groups (Supplementary Table 3 shows the detailed 214 phenotype information used in GWASs).
Then, we meta-analyzed nine GWASs 215 Table 4 for the GWAS summaries), constructed PRSs from the meta-216 analyzed statistics by using a clumping and thresholding method, and performed survival 217 analyses to investigate the association of the derived PRS with individual lifespan (age at 218 death) in the one withheld sub-group. We repeated this analysis ten times and further meta-219 analyzed the statistics of survival analyses in the 10 sub-groups (Figure 2 and Methods for 220 the study design). Thus, we were able to maintain the sample size in GWASs at nine-tenths 221 of the whole cohort and at the same time, validate the derived PRSs using all of the 222 individuals in the cohort. 223
(Supplementary
Among the investigated clinical phenotypes, higher PRSs of blood pressure-related traits 224
(systolic blood pressure [sBP] , diastolic blood pressure [dBP], and mean arterial pressure 225
[MAP]) were significantly associated with a shorter lifespan (Figure 1b ; summary results 226 shown in Supplementary Table 2 ). In the case of sBP, whose PRS showed the strongest 227 association with the age at death (HR of per SD increase in PRS on mortality = 1.03 [1.02- Figure  249 1c), which was not confounded by the variance explained by PRSs in each trait (shown in 250 Supplementary Table 5 ). To summarize, the PRSs have provided novel and distinct insights 251 into prioritizing critical factors affecting human lifespan from the observational studies. 252
In addition to the overall survival outcome, we also tested the cause-specific mortality that 253 drives the association with the sBP PRS, by leveraging the detailed follow-up data in BioBank 254
Japan. Among the four most frequent causes of death in Japan 11 , a high sBP PRS was 255 significantly associated with death from cardiovascular diseases (I01-I02, I05-I09, I20-I25, 256 I27 and I30-I52 [HR = 1.04 (1.01-1.08), P = 0.0064]) and nominally associated with death 257 from cerebrovascular diseases (I60-69 [HR = 1.05 (1.01-1.10), P = 0.024]), as categorized 258 by the International Classification of Diseases 10. We next performed comorbidity-stratified 259 analysis in the association of sBP PRS with lifespan. We found that individuals with a past 260 medical history of type 2 diabetes, cerebral infarction, or dyslipidemia strongly drove the 261 association of sBP PRS with lifespan in Japanese individuals (HR = 1.05 [1.03-1.07), 1.06 262 [1.03-1.09), 1.05 [1.02-1.08), and P = 2.6×10 -5 , 1.9×10 -4 , 4.0×10 -3 , respectively). These 263 results recapitulated the epidemiological knowledge that high blood pressure is one of the 264 strongest risk factors of mortality among patients with cardiovascular 21 , cerebrovascular 22,23 , 265 and metabolic diseases 24 . It has been previously reported that healthy-aging individuals had 266 low genetic risk of coronary artery disease 25 , which is in line with our findings. 267 
Trans-ethnic association study of PRSs of complex traits with human lifespan 279
Next, we sought to replicate these associations in individuals of European ancestry using the 280 individual-level data of UK Biobank (n = 361,194) and FinnGen (n = 135,638). We first 281 constructed the PRSs by adopting the 10-fold LOGO meta-analysis approach when the 282 individual-level phenotype was available (20 out of 33 traits in UK Biobank). Otherwise, we 283 derived the PRSs by using independent publicly available large-scale GWAS summary 284 statistics of European ancestry (13 out of 33 traits in UK Biobank and all the 33 traits in 285
FinnGen) with a linkage disequilibrium (LD) reference of European individuals (Figure 2 and 286
Methods for the study design and Supplementary Table 6 for public GWAS information). In 287 this way, we could calculate the individual PRSs of 33 quantitative traits among the 45 288 investigated traits in BioBank Japan ( Supplementary Table 7 and 8 for phenotype and 289 internal GWAS summary). We then associated the derived PRSs with lifespan in UK Biobank 290
and FinnGen, and finally performed a trans-ethnic meta-analysis across the three cohorts 291 (Summary results are shown in Supplementary Table 9 ). In UK Biobank and FinnGen, we Figure 4d ). To further validate this 297 finding, we also performed a secondary analysis using parental lifespan data in UK Biobank, 298 which offered a much larger statistical power (see Methods for the detailed analysis method). 299
The secondary analysis revealed that a genetically increased risk of sBP was also associated 300 with a shorter parental lifespan (HR = 1.06 [1.06-1.07], P =2.0×10 -86 ). 301
Interestingly, the high PRSs of BMI and body weight (BW) were most significantly 302 associated with short lifespan in UK Biobank and FinnGen (BMI: HR = 1.07 [1.05-1.09] and 303 1.06 [1.04-1.08], P = 1.7×10 -11 and 1.5×10 -8 , respectively), while they showed much smaller 304 effect sizes and less significant associations in BioBank Japan (BMI: HR = 1.01 [1.00-1.02], 305 P = 0.094). We noted that a strong effect of obesity on lifespan was consistent between the 306 two of the European cohorts, UK Biobank and FinnGen, which would suggest the robustness 307 of the result against the methods used for the calculation of PRSs (i.e., LOGO in UK Biobank 308 and usage of independent GWAS summary statistics in FinnGen). Among all the investigated 309 traits, the random effect meta-analyses only revealed a significant heterogeneity in 310 association for BMI and BW (Pheterogeneity = 9.5×10 -8 [BMI] and 1.5×10 -8 [BW]). We did not 311 observe apparent differences in the heritability and variance explained by the PRSs of BMI 312 or BW between in BioBank Japan and UK Biobank ( Supplementary Table 4 , 5, 8 and 10). 313
Thus, we considered that the reasons for this trans-ethnic heterogeneity was not attributed 314 to the differences in GWASs utilized for the derivations of PRSs. The observed trait mean 315 and SD were larger in the European cohorts before normalization (the mean for BMI was To determine what is driving the association of BMI PRS on lifespan (i.e. mortality) in 326
Europeans, we additionally investigated the cause-specific mortality and comorbidity 327 information recorded in UK Biobank. When we tested the association of BMI PRS with the 328 cause-specific mortality in UK Biobank, the BMI PRS was most strongly associated with 329 cerebrovascular death (HR = 1.12 [1.08-1.17], P = 3.1×10 -8 ). When we stratified individuals 330 based on the comorbid conditions (i.e., common disease affection status), we found that the 331 association of BMI PRS with lifespan was strongest among those with unstable angina (HR 332 = 1.17 [1.05-1.30], P = 3.1×10 -3 ). These analyses successfully pinpointed the target 333 individuals who would be expected to benefit most from the modification of obesity. 334
There were several additional traits where the PRSs showed significant associations with 335 lifespan in trans-ethnic meta-analysis after the Bonferroni correction for multiple testing (Pmeta 336 < 1.5x10 -3 ; i.e., lipid-related traits, height, and platelet count). The genetic burden of increased 337 lipid-related traits (i.e. total cholesterol and LDL cholesterol) was associated with a shorter 338 lifespan, which was concordant with the observational studies reporting the causal roles of 339 cholesterol in worse health outcomes 27 . Height has been indicated as a risk factor for various 340 cancers and linked with cancer-related mortality in both Europeans and Asians 15,16 . A lower 341 platelet count was also reported as associated with an increased mortality in Europeans 28 . 342
To test whether there existed differences in the effect sizes of PRS on lifespan between 343 males and females, we performed a sex-stratified association study of PRSs with lifespan 344 across the investigated traits and across the three cohorts. While we did not find any 345 significant differences between sexes within each of the three cohorts ( Supplementary  346   Figure 4a-c) , the sex-stratified trans-ethnic meta-analysis revealed that the effect of high 347 dBP PRS on a short lifespan, which was the largest among 33 traits in primary meta-analysis, 348 was significantly larger in males than in females (HRmale = 1.05 [1.04-1.06], HRfemale= 1.02 349 [1.00-1.03], Pheterogeneity = 0.0013; Supplementary Figure 4d ). This observation was in line 350 with previous epidemiological studies showing that the excess mortality caused by 351 hypertension was higher for men than for women in the Japanese population 29 To summarize, these results collectively suggest the utility of PRSs in genetics-driven 368 identification of both known and novel drivers for longevity, and could potentially pinpoint a 369 group of individuals who could most likely benefit from the intervention. 370 The threshold of significance for the derivation of PRS was set P = 1.0×10 -6 . We further 375 performed a trans-ethnic fixed-effect meta-analysis of the association results from the three 376 Bonferroni correction for multiple testing (P < 1.5x10 -3 ). 380
No evidence of an interaction effect of PRSs of complex traits and lifestyle factors on 381 lifespan 382
Motivated by the identification of biomarkers genetically affecting lifespan, we finally 383 investigated whether there existed any interaction between the PRS of these biomarkers and 384 various lifestyles. As blood pressure PRSs were most strongly associated with lifespan in the 385 Japanese population, we tested the interaction effect between sBP PRS and lifestyle on 386 lifespan in BioBank Japan ( Supplementary Table 11 ). While various lifestyle factors had a 387 strong impact on lifespan ( Supplementary Table 12 ), none of them showed significantly 388 heterogeneous effects on survival according to the sBP PRS status. For example, the 389 beneficial effect of smoking cessation on survival was not significantly different among those 390 with the highest risk of increased blood pressure (Δ10-year mortality = -0.050) or those with 391 the lowest risk of increased blood pressure (Δ10-year mortality = -0.049, interaction P = 0.63) 392 inBioBank Japan. In Europeans, as we found the strongest association between the obesity 393
PRS and lifespan, we investigated the interaction between BMI PRS and lifestyle in UK 394
Biobank. Again, no significant interaction effect on lifespan was observed (Pinteraction > 0.05). 395
Taken together, even people with the high genetic burden of increased blood pressure or 396 obesity could benefit from the modifiable lifestyles such as abstinence from smoking and 397 regular exercise, which could lead to a better survival. 398
Discussion 400
Harnessing a global effort to expand genetic studies in both sample size and the scope of 401 phenotypes, with the additional notion of the importance of population diversity 5 , PRS is 402 expected to identify individuals with inborn health risks in clinics. While early detection and 403 appropriate health communication should contribute to the improvement of health care 33 , the 404 inherited genetic risks of disease onset cannot be modified. 405
We here showed the novel value of PRS study to identify the monitorable phenotypes that 406 genetically affect health outcomes. Our approach has the potential to contribute to the 407 improvement of healthcare because the identified factors can be modified by medical 408 intervention. We showed a global burden of increased blood pressure and obesity as drivers 409 of mortality from genetics. Our study also revealed that those with a genetic burden to cause 410 high blood pressure or obesity could benefit from healthy lifestyles to the same degree as 411 those without. If those with high-risk alleles are to be notified about their own risks, the early 412 lifestyle modification and medical attention should prevent their premature death. Of note, 413 the magnitude of the effect size in which the PRS of the trait was associated with lifespan 414 was relatively small. However, the magnitude of effect size in which the trait itself (e.g., blood 415 pressure or obesity) affects lifespan, or in which the modification of the trait (e.g., proper 416 blood pressure management or healthy diet) would improve health outcomes, would be 417 expected to be larger in terms of population health. 418
In order to improve population health, we need to decide on how to prioritize the 419 numerous health issues. The observational studies could partly address this point, but the 420 biggest challenge has been that we cannot infer the cause-and-effect direction. While RCTs 421 have been the gold standard to provide robust evidence of the effect of risk factors on health 422 outcomes, they are not always feasible because conducting RCTs (i.e. recruitment, random 423 allocation, treatment, and follow-up etc.) takes a huge amount of resources, which hampers 424 the application to diverse phenotypes. Our approach, which leverages genetic and 425 phenotypic information already existing in biobanks, would have the potential to support the 426 clinical evidence, or to identify candidate risk factors to bring into RCTs. We also note that 427 in-depth analyses, such as those leveraging cause-specific mortality and comorbidity data, 428 could pinpoint target individuals who could most likely benefit from medical attention and 429 intervention. These insights would also be useful in designing efficient RCTs or providing 430 individualized medical evidence. 431
Notably, the genetics-driven identification of critical factors for health outcomes was made 432 possible by trans-ethnic, large-scale, and deep-phenotyped biobanks. The trans-biobank 433 collaboration provided (i) a large sample size, which was critical in analyzing mortality data, 434
(ii) the opportunity for replication, which made our findings robust to cohort-specific 435 confounders, (iii) a trans-ethnic comparison as in the example of obesity, (iv) the validation 436 of our methodology (i.e., we confirmed the coherent result between LOGO and independent 437
GWAS), and (v) the integration of cohort-specific data, such as parental lifespan data in UK 438
Biobank. Nation-wide biobanks, such as those in this study, are prospectively collecting 439 deep phenotype and health outcomes of genotyped individuals, and our proof-of-concept 440 approach would be expected to discover the actionable traits driving health outcomes on a 441 global scale if further applied to diverse and larger populations. 442
This study has potential limitations. First, as BioBank Japan is a hospital-based cohort, it 443 does not represent the Japanese population as a whole. However, since we performed the 444 survival analyses with an adjustment for the disease status and principal components 445 followed by sensitivity analyses, our main result was not confounded by the proportion of 446 patients with a specific disease group (Supplementary Figure 6) or population stratification. 447
Of note, UK Biobank generally enrolls healthy-volunteers 34 . The directional concordance of 448 statistics in BioBank Japan with those in UK Biobank should further support the robustness 449 of the results and mitigates the concern on potential biases due to the differences in genetic 450 structure and environmental interactions. Second, it is unclear whether the PRSs of the traits 451 that showed less significant results in our study were not associated with lifespan because 452 there is truly no relationship, because the PRS did not sufficiently explain the variance of the 453 investigated phenotype, or because there was a strong effect of rare variants, which were 454 not captured in our study. Third, the polygenic effect of the variants constituting the PRSs 455 which also partially affect other traits (pleiotropy), might have coexisted with the association 456 of the PRS of a specific trait with lifespan. Further integration with novel statistical methods 457 to handle and disentangle pleiotropy and desirably RCTs, if feasible, are warranted to obtain 458 clearer insights into the true effect of the complex trait on human lifespan. Fourth, there is 459 currently no consensus on how to optimize and harmonize the P value threshold in calculating 460
PRSs across different cohorts. Our strategy was to set a fixed P value threshold of 1×10 -6 in 461 the trans-ethnic meta-analysis, because we could not obtain trait-specific best P values for 462 every trait which should be optimized to maximize the variance explained by using individual-463 level phenotype data. We confirmed that association statistics (i.e. coefficients) from the fixed 464 threshold of 1×10 -6 was fairly concordant with those from best P values (Pearson's r = 0.85 465 and P = 2.5×10 -13 in BioBank Japan, and r = 0.93 and P = 1.3×10 -9 in UK Biobank). 466
Nevertheless, we consider that further implementation of the methodology for optimally 467 harmonizing PRSs across different cohorts is still warranted. Fifth, it is possible that spouse-468 pairs in biobanks might have caused a subtle bias the GWAS and PRSs-lifespan association 469 if assortative mating exists 35 . Sixth, although we exhaustively checked the cohort-level 470 overlap across biobanks and previous GWASs used in this study, we could not completely 471 exclude the possibility of individual-level overlap, which would be technically difficult to detect 472 as a general point in large-scale genetic studies. Last, the statistical power in the association 473 study with lifespan was limited, partly due to a relatively short follow-up period. This was 474 particularly the case in UK Biobank, which is a recently launched population-based cohort, 475 and only a small number of people have died during the follow-up period. We complemented 476 this point by utilizing parental lifespan data in UK Biobank as a secondary analysis. Since the 477 participants of the biobanks in this study are ongoingly followed-up, the larger number of 478 mortality records in the future would provide us with an opportunity to further validate the 479 robustness of our results. 480
In conclusion, through trans-ethnic biobank collaboration, we demonstrated that blood 481 pressure and obesity were genetically associated with the lifespan of the current generation 482 on a global scale. A comparison across different populations and the integration with deep 483 phenotype data further pinpointed a group of individuals who would be expected to benefit 484 most from the intervention of these traits. With global biobanks' ongoing efforts-enrolling 485 individuals from diverse background and collecting granular phenotype along with health 486 outcomes-we have shown a potential application of genetics to improve population health 487 by providing information of common and modifiable risk factors driving our health outcomes. 488
Methods 509

Study Populations, genotyping and imputation 510
BioBank Japan 511
Clinical information and genotype data were obtained from BioBank Japan (BBJ) project 10,12 , 512 which is a prospective biobank that collaboratively collected DNA and serum samples from Detailed participant information is summarized in Supplementary Table 1a . 518
We genotyped participants with the Illumina HumanOmniExpressExome BeadChip or a 519 combination of the Illumina HumanOmniExpress and HumanExome BeadChips. The quality 520 control (QC) of participants and genotypes was described elsewhere 36 . In this project, we 521 analyzed 179,066 participants of Japanese ancestry as determined by the principal 522 component analysis (PCA)-based sample selection criteria. The genotype data was further 523 imputed with 1000 Genomes Project Phase 3 version 5 genotype (n = 2,504) and Japanese 524 whole-genome sequencing data (n = 1,037) 36 using Minimac3 software. After the imputation, 525
we excluded variants with an imputation quality of Rsq < 0.7 or those with a minor allele 526 frequency (MAF) < 1%. 527
528
UK Biobank 529
The UK Biobank project is a population-based prospective cohort that recruited 530 approximately 500,000 people aged between 40-69 years from 2006 to 2010 from across 531 the United Kingdom (summary in Supplementary Table 1b ; see URLs). Deep phenotype 532 data, such as electronic medical records, lifestyle indicators and bioassays, and genotype 533 data were available for most of the participants. The genotyping was performed using either 534 the Applied Biosystems UK BiLEVE Axiom Array or the Applied Biosystems UK Biobank 535
Axiom Array. The genotypes were further imputed using a combination of the Haplotype 536
Reference Consortium, UK10K, and 1000 Genomes Phase 3 reference panels by IMPUTE4 537 software. The detailed characteristics of the cohort were previously extensively described 34 . 538
In this project, we analyzed 361,194 individuals of white British genetic ancestry as 539 determined by the PCA-based sample selection criteria (see URLs). We excluded the 540 variants with (i) INFO score ≤ 0.8, (ii) MAF ≤ 0.0001 (except for missense and protein-541 truncating variants annotated by VEP 37 , which were excluded if MAF ≤ 1 × 10 -6 ), and (iii) 542 HWE P ≤ 1 × 10 -10 . All of the analyses were conducted via application 31063. 543
544
FinnGen 545
FinnGen is a public-private partnership project combining genotype data from Finnish 546 biobanks and digital health record data from Finnish health registries (see URLs). Six 547 regional and three country-wide Finnish biobanks participate in FinnGen. Additionally, data 548 from previously established population and disease-based cohorts are utilized. Participants' 549 health outcomes are followed up by linking to the national health registries , 550 which collect information from birth to death. We used the genotype and phenotype data of 551 135,638 participants in this study, excluding population outliers via PCA (summary in 552 Supplementary Table 1c ). These individuals were genotyped with the FinnGen1 553
ThermoFisher array and previous cohorts were genotyped with various genotyping arrays. 554
The genotype data was imputed using whole genome sequencing data from 3,775 Finnish 555 individuals by beagle4.1 software (see URLs) 38 . After the imputation, we excluded variants 556 with an imputation INFO score < 0.8 or MAF < 0.0001. 557 558 559
Survival analysis of clinical phenotypes 560
We used Cox proportional hazard models to test the association of clinical phenotypes with 561 lifespan (age at death) in BioBank Japan as described elsewhere 39 . In order to obtain and 562 compare the HRs for the all-cause mortality across the traits, we scaled each trait to have 563 zero mean and unit variance by Z-score transformation. The primary analyses included 564 adjustment for sex, the 47-disease status and the top 20 principal components, which were 565 supposed to account for possible confounders and population stratification. Additional 566 summaries of clinical phenotypes and the number of samples without missing values are 567 described in Supplementary Table 3 . We next performed the same survival analyses in 20 568 clinical phenotypes where individual-level phenotype data was available in UK Biobank 569
( Supplementary Table 7 ). We used Cox proportional-hazard models to test the association 570 of these clinical phenotypes with lifespan (age at death) with an adjustment for sex and the 571 top 20 principal components as covariates. 572 573 574
Genome-wide association studies 575
BioBank Japan 576
33
In order to derive population-specific PRSs of BioBank Japan, we first split the cohort into ten 577 sub-groups. We then conducted GWASs for 45 quantitative traits within each of the ten sub-578 groups. We performed the linear regression assuming the additive effect of the imputed 579 dosage of each variant by PLINK 40 . For individuals taking anti-hypertensive medications, we 580 added 15 mmHg to their sBP and 10 mmHg to their dBP and derived their MAP and pulse 581 pressure (PP) using the adjusted sBP and dBP. We also added smoking status as a covariate 582 for blood pressure-related traits. Other trait-specific covariates, adjustment for medications, 583
and sample exclusion criteria are described in Supplementary Table 13 and elsewhere 41 . 584
We next meta-analyzed the statistics from nine sub-groups by the inverse-variance method 585 assuming the fixed-effect ten times, with keeping one sub-group away from the meta-analysis 586 for PRS derivation and validation each time (a 10-fold leave-one-group-out [LOGO] meta-587 analysis approach). Before performing LOGO, we excluded genetically related individuals 588 from the cohort, based on PI_HAT > 0.125, as calculated by PLINK software. We note that 589 we adopted this strategy to obtain precise estimates of the HR, not to maximize R 2 value, 590 which will be maximized when we have the largest GWAS samples. We applied LD Score 591 Regression (LDSC) 42 to the meta-analyzed summary statistics to estimate the heritability and 592 potential population stratification. We also performed cross-trait LDSC 43 to compare the 593 statistics from the LOGO GWAS (meta-analysis of 9 subgroup GWASs) and those from the 594 conventional GWAS (using all the individuals in the cohort). The summary results of the 595 GWASs are described in Supplementary Table 4 . 596
597
UK Biobank 598
We applied the ten-fold LOGO approach to 20 clinical phenotypes for which individual-level 599 phenotype data in UK Biobank was available ( Supplementary Table 7 ). We performed 600
GWASs using the linear regression model in Hail v0.2 (see URLs) with covariates including 601 age, age 2 , sex, and the top 20 principal components. For blood pressure traits, we added 15 602 mmHg and 10 mmHg to sBP or dBP, respectively, if individuals are taking anti-hypertensive 603 medication and derived the MAP and PP using the adjusted sBP and dBP. We also added 604 smoking status as a covariate for blood pressure-related traits. We again performed cross-605 trait LDSC 43 to compare the statistics from the LOGO GWAS and those from the conventional 606 GWAS, for which we used summary statistics from Dr. Benjamin Neale's lab (see URLs). 607
The summary results of the meta-analyzed GWASs are described in Supplementary Table  608 8. For the additional 13 traits among the remainder of the 25 traits investigated in BioBank 609 Japan, we were able to collect independent large-scale GWAS summary statistics of 610 European ancestry, either from publicly available websites or upon request to the authors. 611
The information of these 13 GWASs is described in Supplementary Table 6 . 612 613 FinnGen 614
We did not perform within-cohort GWASs for the FinnGen cohort because the availability of 615 individual-level phenotype data was limited. For the 20 traits where we performed LOGO in 616 UK Biobank, we referred to UK Biobank GWAS summary statistics from all 361,194 white 617 British individuals. With the exception of C-reactive protein (CRP), for 12 traits among the 13 618 traits where we used independent GWAS summary statistics in UK Biobank, we utilized the 619 same GWAS summary statistics, as we confirmed that there was no apparent cohort overlap 620 with FinnGen ( Supplementary Table 6 ). For CRP, since the GWAS of Ligthart et al. included 621 the FINRISK Study, which was also involved in FinnGen, we additionally performed GWAS 622 in UK Biobank individuals (n = 353,466). When performing CRP GWAS in UK Biobank, we 623 excluded the individuals with autoimmune or inflammatory diseases. 624 625 626
Construction of Polygenic Risk Scores 627
BioBank Japan 628
By referring to the effect sizes and P values of ten summary results from meta-analyzed 629
GWASs of nine sub-group GWASs, we derived the PRSs of individuals in the one withheld 630 sub-group using a clumping and thresholding method. First, we performed LD clumping on 631 the meta-analyzed GWAS summary statistics with PLINK software using 5,000 randomly 632 selected BioBank Japan participants as the LD reference. Briefly, we first used PLINK to 633 clump all the variants using the following flags: --clump-p1 1 --clump-p2 1 --clump-r2 0.1 --634 clump-kb 1000. We then computed PRSs for variants meeting the following P value 635 thresholds: 5×10 -8 , 5×10 -7 , 1×10 -6 , 1×10 -4 , 1×10 -3 , 1×10 -2 , 5×10 -2 , 0.1, 0.2, 0.5, and 1. In the 636 one withheld sub-group, we derived PRSs by multiplying the dosage of risk alleles for each 637 variant by the effect size in the GWAS and summing the scores across all the selected 638 variants. We quantified the trait variance explained by the derived PRSs in individuals within 639 the withheld sub-group, by calculating the adjusted R 2 attributable to the PRSs from nested 640 models, in which the full linear model was the trait value ~ PRS + all covariates and the 641 nested model dropped only the PRS term ( Supplementary Table 5 ). 642
643
UK Biobank and FinnGen 644
to be used as instrumental variables, we performed GWASs within the GWAS group for these 737 traits with the same covariates described earlier, and selected independent genetic variants 738 with PGWAS < 1.0×10 -6 for each trait (lead variants at significant loci at least +-500 kb distant 739 from each other). We next performed association study of these genetic variants with lifespan 740 within the MR group, by using the same Cox proportional-hazard model described earlier. By 741 using these genetic variants and association estimates, we obtained the effect estimate of 742 the exposure (biomarker) on the outcome (lifespan) by pooling all MR estimates using the 743 fixed-effects inverse-variance weighted method 48 . 744
For the traits where we used independent GWAS summary statistics in PRS calculation 745 (i.e. 13 traits in UK Biobank and 33 traits in FinnGen), we selected independent genetic 746 variants with PGWAS < 1.0×10 -6 from these statistics. We next performed association study of 747 these genetic variants with lifespan in a whole cohort, by using the same Cox proportional-748 hazard model. These estimates are used to obtain the MR effect estimate by inverse-variance 749 weighted method. 750
We finally performed the fixed-effect meta-analysis of these effect estimate in MR from 751 each of the three cohorts. 752 753 754
